Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ACAD vs CRSP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACAD Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

ACAD Overall Winner 6-Pillar Tally: ACAD 5 – 1 CRSP Matrix Metrics: ACAD 6 – 4 CRSP

As of Nov 16, 2026, Acadia Pharmaceuticals Inc. (ACAD) is the stronger overall head-to-head candidate over CRISPR Therapeutics AG (CRSP) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ACAD carries a Unified Composite Score of 42.0/100 (HOLD) at $19.07 (17.8x Forward P/E, 10.2% operating margin), whereas CRSP carries 44.7/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin).

  • Composite vs. Pillar Nuance: While CRSP currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. ACAD 42.0/100 HOLD), ACAD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (10.2% vs. -2058.6% operating margin) and revenue trajectory (+22.8% vs. +1325.1% YoY).
  • Technical & Structure Timing Caution: ACAD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.0); meanwhile CRSP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACAD vs CRSP
ACAD NASDAQ Head-to-Head Winner
Acadia Pharmaceuticals Inc.
Pharmaceutical Preparations
$19.07
+1.71% 1D
Market Cap $3.1B
TTM Revenue $1.20B
Forward P/E 17.8x
Beta / 30D Vol 0.11β · 93% Vol
Unified Composite Score
42.0 / 100 HOLD
Tech 43.0 Fund 52.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.8%), weak momentum, RSI 44
RSI-14: 44.0 · SMA20: $19.82 · SMA50: $21.61
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
TTM Revenue $25M
Forward P/E 23.4x
Beta / 30D Vol 1.85β · 60% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 25.0 Fund 52.0 Flow 68.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.6%), weak momentum, RSI 30
RSI-14: 29.6 · SMA20: $48.84 · SMA50: $51.79

6-Pillar Scorecard Institutional Category Breakdown (ACAD 5 – 1 CRSP)

Columns: Metric · ACAD · CRSP
1. Valuation Multiples ACAD
Forward P/E 17.8x 23.4x
Trailing P/E 8.6x 23.4x
PEG Ratio N/M N/M
EV / Revenue 2.4x N/M
2. Growth & Scale CRSP
Revenue Growth (YoY) +22.8% +1325.1%
Earnings Growth (YoY) -26.2% +0.0%
TTM Revenue (USD) $1.20B $25M
Market Cap $3.1B $4.1B
3. Profitability & Quality ACAD
Gross Margin 63.9% N/A
Operating Margin 10.2% -2058.6%
Net Profit Margin 30.1% 0.0%
Return on Equity (ROE) 31.4% -25.6%
4. Balance Sheet & Cash Flow ACAD
Cash Generation (TTM) $181M -$378M
Cash Flow Margin 15.0% N/A
Net Cash / Leverage $251M Net Cash $588M Net Debt (0.47x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ACAD
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 42.6% (4th %ile) 97.8% (52nd %ile)
Put/Call OI Skew 0.33x (Call-Skewed) 0.65x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat ACAD
OpEx & R&D Intensity 53.7% of Rev ($646M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACAD (6) vs CRSP (4)
Institutional Metric ACAD CRSP Criterion Row Edge
Market Capitalization
Scale
$3.1B $4.1B Larger Scale CRSP
Trailing P/E Ratio
Valuation
8.6x 23.4x Lower Multiple ACAD
Forward P/E Ratio
Valuation
17.8x 23.4x Lower Multiple ACAD
Revenue Growth (YoY)
Growth
+22.8% +1325.1% Higher Growth CRSP
Operating Margin (TTM)
Profitability
10.2% -2058.6% Higher Margin ACAD
Net Profit Margin
Profitability
30.1% 0.0% Higher Margin ACAD
Return on Equity (ROE)
Capital Efficiency
31.4% -25.6% Higher ROE ACAD
52-Week Range Position
Momentum
21% ($16–$31) 1% ($40–$63) Stronger Trend ACAD
Beta / 30D Volatility
Risk Regime
0.11β · 93% Vol 1.85β · 60% Vol Lower Realized Risk CRSP
Unified Institutional Score
Composite Signal
42.0 / 100 (HOLD) 44.7 / 100 (HOLD) Higher Composite CRSP
Trailing 12M Revenue (USD)
Operating Scale
$1.20B $25M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
63.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$181M ($251M Net Cash) -$378M ($588M Net Debt (0.47x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACAD +17.28 pp
ACAD: -0.26% · CRSP: -17.54%
3M Horizon CRSP +13.48 pp
ACAD: -36.81% · CRSP: -23.33%
6M Horizon ACAD +8.54 pp
ACAD: -7.83% · CRSP: -16.37%
1Y Horizon ACAD +1.21 pp
ACAD: -19.33% · CRSP: -20.54%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ACAD Revenue CRSP Revenue ACAD Op. Margin CRSP Op. Margin Margin Leader
FY2018 $220M $0M -110.6% -5087.8% ACAD
FY2019 $340M $290M -72.7% 16.1% CRSP
FY2020 $440M $0M -64.9% -49295.5% ACAD
FY2021 $480M $910M -35.2% 40.8% CRSP
FY2022 $520M $0M -43.2% -56190.4% ACAD
FY2023 $730M $370M -10.1% -60.0% ACAD
FY2024 $960M $40M 24.1% -1250.4% ACAD
FY2025 $1.07B $0M 9.8% -18933.6% ACAD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACAD BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 42.6%
IV Percentile 4th %ile
Put/Call OI Skew 0.33x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ACAD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRSP BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 97.8%
IV Percentile 52nd %ile
Put/Call OI Skew 0.65x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CRSP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACAD Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $3.1B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment 53.7% of Rev ($646M)
90D Engineering Disclosures 0 Published
CRSP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.1B market capitalization and -2058.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ACAD vs CRSP Key Questions & Quantitative Answers

As of Nov 16, 2026, Acadia Pharmaceuticals Inc. (ACAD) is the stronger overall head-to-head candidate over CRISPR Therapeutics AG (CRSP) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ACAD carries a Unified Composite Score of 42.0/100 (HOLD) at $19.07 (17.8x Forward P/E, 10.2% operating margin), whereas CRSP carries 44.7/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin). Composite vs. Pillar Nuance: While CRSP currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. ACAD 42.0/100 HOLD), ACAD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (10.2% vs. -2058.6% operating margin) and revenue trajectory (+22.8% vs. +1325.1% YoY). Technical & Structure Timing Caution: ACAD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.0); meanwhile CRSP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRSP leads the Growth & Scale pillar: ACAD posts +22.8% YoY revenue growth and -26.2% YoY earnings growth on $1.20B TTM revenue (63.9% gross margin, 10.2% operating margin), compared with CRSP at +1325.1% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -2058.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ACAD cumulative revenue shifted +386.4% while CRSP shifted -86.2%. In operating R&D and SG&A reinvestment, ACAD deploys 53.7% of Rev ($646M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CRSP.

ACAD screens cheaper on headline valuation multiples. ACAD trades at 17.8x Forward P/E, 8.6x Trailing P/E, N/M PEG, and 2.4x EV/Revenue (15.0% FCF margin), whereas CRSP trades at 23.4x Forward P/E, 23.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACAD (31.4% ROE) versus CRSP (-25.6% ROE) capital efficiency.

In options market volatility and institutional positioning, ACAD carries 42.6% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.33x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.11β · 93% Vol realized risk). By comparison, CRSP carries 97.8% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.65x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.85β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.